Golan Theo Dov
Division of Clinical Immunology, Bnai Zion Medical Center, POB 4940, Haifa, IL-31048, Israel.
Curr Rheumatol Rep. 2002 Feb;4(1):18-24. doi: 10.1007/s11926-002-0019-8.
The inflammatory process of systemic lupus erythematosus (SLE) vasculitis occurs in up to 56% of patients with SLE, whereas the vaso-occlusive incidence of antiphospholipid syndrome in SLE (which is not exclusive of SLE vasculitis) reaches up to 15%. Both situations can be life-threatening, requiring the appropriate therapeutic approach. Aggressive anti-inflammatory therapy is used in the case of SLE vasculitis and aggressive antithrombotic/anticoagulant treatment in the other. However, often the differential diagnosis between the two entities is difficult to achieve, especially when a tissue biopsy to help establish the diagnosis is topographically difficult to obtain or is clinically contraindicated. Such situations are discussed and appropriate guidelines for a correct diagnosis suggested.
系统性红斑狼疮(SLE)血管炎的炎症过程在高达56%的SLE患者中出现,而SLE中抗磷脂综合征的血管闭塞发生率(这不排除SLE血管炎)高达15%。这两种情况都可能危及生命,需要采取适当的治疗方法。对于SLE血管炎采用积极的抗炎治疗,而对于另一种情况则采用积极的抗血栓/抗凝治疗。然而,通常很难对这两种情况进行鉴别诊断,尤其是当有助于确立诊断的组织活检在地形上难以获取或临床上存在禁忌时。本文讨论了此类情况,并提出了正确诊断的适当指南。